

Prunella L Blinman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2735883/publications.pdf>

Version: 2024-02-01

37
papers

486
citations

687363

13
h-index

752698

20
g-index

39
all docs

39
docs citations

39
times ranked

781
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey. <i>Supportive Care in Cancer</i> , 2022, 30, 511-519.	2.2	12
2	The utility of surveillance CT scans in a cohort of survivors of colorectal cancer. <i>Journal of Cancer Survivorship</i> , 2022, , 1.	2.9	1
3	The long haul: Lived experiences of survivors following different treatments for advanced colorectal cancer: A qualitative study. <i>European Journal of Oncology Nursing</i> , 2022, 58, 102123.	2.1	9
4	PEARL: A randomised phase 3 trial of palliative care early in advanced lung cancers (ALTG/TOGA 13/008).. <i>Journal of Clinical Oncology</i> , 2022, 40, 12020-12020.	1.6	0
5	Factors associated with fear of cancer recurrence in breast and colorectal cancer survivors: A cross-sectional study of cancer survivors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 222-229.	1.1	10
6	Why do delays to diagnosis and treatment of lung cancer occur? A mixed methods study of insights from Australian clinicians. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e77-e86.	1.1	3
7	Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. <i>Translational Lung Cancer Research</i> , 2021, 10, 1623-1634.	2.8	5
8	Scanxiety: a scoping review about scan-associated anxiety. <i>BMJ Open</i> , 2021, 11, e043215.	1.9	40
9	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2021, 155, 28-33.	2.0	18
10	Experiences with scans and scanxiety in people with advanced cancer: a qualitative study. <i>Supportive Care in Cancer</i> , 2021, 29, 7441-7449.	2.2	12
11	Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours. <i>Internal Medicine Journal</i> , 2021, 51, 955-959.	0.8	4
12	Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa107.	2.9	2
13	456...A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIb/IV non-small cell lung cancer (NSCLC): The LANDSCAPE 1011 trial in progress. , 2021, 9, A484-A484.		0
14	Estimating survival time in older adults receiving chemotherapy for advanced cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 617-625.	1.0	8
15	Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferences. <i>Journal of Geriatric Oncology</i> , 2020, 11, 626-632.	1.0	10
16	Utilisation of Adjuvant Chemotherapy and 5-Year Survival Analysis of Prospectively Recorded Cohort Data for Older Adults Versus Younger Adults with Resected Primary Colon Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 988-997.	1.3	0
17	Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 547-558.	2.3	5
18	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. <i>ESMO Open</i> , 2020, 5, e001090.	4.5	18

#	ARTICLE	IF	CITATIONS
19	Patients' experience of lung cancer care coordination: a quantitative exploration. <i>Supportive Care in Cancer</i> , 2019, 27, 485-493.	2.2	19
20	Patterns of care and survival of older patients with malignant pleural mesothelioma. <i>Journal of Geriatric Oncology</i> , 2019, 10, 573-576.	1.0	2
21	Paradigm shift in local consolidative therapy for oligometastatic non-small cell lung cancer: a meta-analysis. <i>Annals of Translational Medicine</i> , 2019, 7, S320-S320.	1.7	0
22	Pharmacokinetics of Anticancer Drugs Used in Treatment of Older Adults With Colorectal Cancer: A Systematic Review. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 553-560.	2.0	4
23	Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement. <i>Journal of Geriatric Oncology</i> , 2019, 10, 202-209.	1.0	40
24	Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 210-215.	1.0	6
25	Older adults' preferred and perceived roles in decision making about palliative chemotherapy: Their decision priorities, and information preferences.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11546-11546.	1.6	1
26	Estimating survival time in older adults receiving chemotherapy for advanced cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23017-e23017.	1.6	1
27	Times to Diagnosis and Treatment of Lung Cancer in New South Wales, Australia: A Multicenter, Medicare Data Linkage Study. <i>Journal of Oncology Practice</i> , 2018, 14, e621-e630.	2.5	9
28	How long is too long? A scoping review of health system delays in lung cancer. <i>European Respiratory Review</i> , 2018, 27, 180045.	7.1	55
29	Delays to diagnosis and treatment of lung cancer in Australia: healthcare professional perceptions of actual versus acceptable timeframes. <i>Internal Medicine Journal</i> , 2018, 48, 1063-1071.	0.8	4
30	Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying. <i>Internal Medicine Journal</i> , 2018, 48, 774-779.	0.8	22
31	Understanding Immune Tolerance of Cancer: Re-purposing Insights from Fetal Allografts and Microbes. <i>BioEssays</i> , 2018, 40, e1800050.	2.5	8
32	Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1321-1340.	3.0	17
33	Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. <i>British Journal of Cancer</i> , 2016, 115, 1179-1185.	6.4	19
34	Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?. <i>European Journal of Cancer</i> , 2015, 51, 1529-1537.	2.8	23
35	Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 359.	2.2	16
36	The shortage of medical oncologists: the Australian Medical Oncologist Workforce Study. <i>Medical Journal of Australia</i> , 2012, 196, 58-61.	1.7	45

#	ARTICLE	IF	CITATIONS
37	Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?. European Journal of Cancer, 2010, 46, 1800-1807.	2.8	37